Individualizing antipsychotic treatment selection in schizophrenia: characteristics of empirically derived patient subgroups

Autor: R. Sturlason, Mathias Zink, Ilkka Larmo, José Manuel Montes, Pedro Levy, Andrea Fagiolini, Alessandro Rossi, Christoph U. Correll, G. Papageorgiou, Fernando Cañas

Publikováno v: Correll, C U, Cañas, F, Larmo, I, Levy, P, Montes, J-M, Fagiolini, A, Papageorgiou, G, Rossi, A, Sturlason, R & Zink, M 2011, ' Individualizing antipsychotic treatment selection in schizophrenia : characteristics of empirically derived patient subgroups ', European Psychiatry, vol. 26 Suppl 1, pp. 3-16 . https://doi.org/10.1016/S0924-9338(11)71709-6
Scopus-Elsevier

Treatment of schizophrenia with antipsychotic drugs is frequently sub-optimal. One reason for this may be heterogeneity between patients with schizophrenia. The objectives of this study were to identify patient, disease and treatment attributes that

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1544f848bb9a0a1776b35c8b74760ecd
https://doi.org/10.1016/s0924-9338(11)71709-6

Oral risperidone plus oral lorazepam versus standard care with intramuscular conventional neuroleptics in the initial phase of treating individuals with acute psychosis

Autor: Rossella Medori, Joseph Lejeune, Roel Witte, Ilkka Larmo, Andreas Schreiner, Alice Lex, Athanasios Karavatos, Wlodzimierz Chrzanowski

Publikováno v: International Clinical Psychopharmacology. 19:259-269

Although atypical antipsychotics are now considered first line treatments for schizophrenia, intramuscular (i.m.) conventional neuroleptics are often still considered necessary in emergency treatment of acute psychoses. This European, multicentre, op

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f0dd957ffc6e80ff252e83e692aca61
https://doi.org/10.1097/01.yic.0000138820.78121.0e

Strategies for successful clinical management of schizophrenia with ziprasidone

Autor: Alessandro Rossi, G. Papageorgiou, Pedro Levy, Bernd Gallhofer, Ilkka Larmo, Fernando Cañas, Mathias Zink, José Manuel Montes, Andrea Fagiolini

This review addresses practical clinical issues related to the use of ziprasidone in the treatment of schizophrenia using information from clinical trials, unpublished data, manufacturer's information, and input from an expert faculty of European psy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8986113e7ed435bd76222d8ae3625f4a
http://hdl.handle.net/11365/26713

Antipsychotic drug treatment in the prodromal phase of schizophrenia

Autor: Alo Juriloo, Matti O. Huttunen, Minna Dahlström, Pirkko Räsänen, Ilkka Larmo, Tyrone D. Cannon

Publikováno v: The American journal of psychiatry. 159(7)

OBJECTIVE: The safety and tolerability of short-term treatment with a low dose of risperidone was evaluated in adolescents with prodromal symptoms and a family history of schizophrenia. METHOD: Four prodromal high-risk adolescents and six first-episo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3f7c29c7fe6c58b5349d08417d3420a
https://pubmed.ncbi.nlm.nih.gov/12091205